|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, overexpression of TPD52 in CRC SW480 cells showed an increased cell migration (P = 0.023) and invasion (P = 0.012) through inducing occurrence of epithelial-mesenchymal transition (EMT) and activating focal adhesion kinase (FAK)-mediated integrin signalling and PI3K⁄Akt signalling.Whereas TPD52-depleted cells showed the reverse effect.
|
28562687 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, phosphatase gene and its downstream AKT and PI3K expression levels can be regulated by regulating the expression levels of miR-21, which in turn regulates the development of CRC.
|
27350731 |
2016 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Arginine ADP-ribosyltransferase 1 promotes angiogenesis in colorectal cancer via the PI3K/Akt pathway.
|
26847718 |
2016 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, this compound was revealed to be a selective PI3K‑Akt‑mTOR pathway inhibitor, and may be a potent anticancer agent for the treatment of CRC, as it restrains the proliferation of CRC cells.
|
24398569 |
2014 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is growing body of data evaluating the value of PI3K/AKT/mTOR inhibitors in CRC (e.g., BEZ235, NVP-BEZ235, OSI-027, everolimus, MK-2206, KRX-0401, BYL719, and BKM120).
|
28230287 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, we show that P. anaerobius drives CRC via a PCWBR2-integrin α<sub>2</sub>/β<sub>1</sub>-PI3K-Akt-NF-κB signalling axis and identify the PCWBR2-integrin α<sub>2</sub>/β<sub>1</sub> axis as a potential therapeutic target for CRC.
|
31501538 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, combination of RTK and MEK inhibitors led to concomitant inhibition of PI3K and MEK signaling, marked growth suppression, and robust apoptosis of human KRAS mutant colorectal cancer cell lines in vitro and upon xenografting in mice.
|
21985784 |
2011 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
H19 regulates PI3K-Akt signal pathway through a competing endogenous RNA network and predicts poor prognosis in colorectal cancer.
|
31164794 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
|
23826249 |
2013 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CONCLUSIONS OPN promoted cell proliferation, migration, and invasion, and was accompanied by upregulation of ALDH1-positive CSC in CRC through activation of PI3K-Akt-GSK/3ß-ß/catenin pathway.
|
31017126 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TNKS/PI3K/EGFR inhibition also efficiently reduced growth of both COLO320DM and HCT-15 tumor xenografts <i>in vivo</i> At the highest doses, tumor xenograft growth was halted without affecting the body weight of the tested animals.<b>Implications:</b> Combining TNKS inhibitors with PI3K and EGFR inhibition may expand the therapeutic arsenal against colorectal cancers.<i></i>.
|
29222171 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pathway analysis revealed multiple pathways including Jak-STAT, TGF-beta, PI3K-Akt and MAPK signaling pathway that are correlated to colorectal cancer.
|
29496555 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Somatic mutations in PIK3CA (phosphatidylinositol-4,5-bisphosphonate 3-kinase [PI3K], catalytic subunit alpha gene) activate the PI3K-AKT signaling pathway and contribute to pathogenesis of various malignancies, including colorectal cancer.
|
24231454 |
2013 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pathway analysis of the target genes regulated by the five most highly expressed miRNAs uncovered a significant number of genes involved in the CRC pathway, including APC, TGFβ and PI3K, thus suggesting that these miRNAs are relevant in CRC.
|
23824282 |
2013 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer.
|
26718987 |
2016 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on the above‑mentioned results, the dual PI3K/mTOR and ATP‑competitive mTOR inhibitors have demonstrated high potential for targeting the mTOR pathway in CRC.
|
29845289 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, signaling pathways that are important in CRC (e.g. the WNT, MAPK, TGF-β, TP53 and PI3K pathways) are regulated by miRNAs.
|
27573904 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical staining demonstrated loss of PTEN protein in 54.5% (24/44) of CRCs and no significant difference in PI3K p110α expression between CRCs and the adjacent normal colonic mucosa (p = 0.380).
|
23992303 |
2013 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We examined the expression of genes related to the PI3K/Akt and Wnt pathways at the transcriptional and translational levels in a DMH-induced rat CRC model following IP6 administration.
|
28315345 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FAT4 regulates the EMT and autophagy in colorectal cancer cells in part via the PI3K-AKT signaling axis.
|
30832706 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma.
|
20130434 |
2009 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Likewise, pharmacological blockade of PI3K/Akt and NF-κB pathways mitigated the CRC pro-survival effects of TLR2 stimulation.
|
29689497 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FOXQ1 promotes cancer metastasis by PI3K/AKT signaling regulation in colorectal carcinoma.
|
28559972 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The added predictive value of additional biomarkers in the RAS-RAF-MAPK and PI3K-AKT-mTOR pathways in colorectal cancer is uncertain, which led us to systematically review the impact of alterations in KRAS (outside of exon 2), NRAS, BRAF, PIK3CA and PTEN in relation to the clinical benefit from anti-EGFR treatment.
|
24666267 |
2014 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PNPs entrapping PI3K inhibitors (i.e., wortmannin and PX866) suppressed CRC lung metastasis growth, and SN-38-loaded PNPs completely eliminated CRC lung metastasis.
|
29421609 |
2018 |